Familial partial lipodystrophy (FPLD) is characterised by a partial loss of subcutaneous fat in the limbs. It also results in excessive adipose tissue around the neck and face with variable involvement of the trunk. It has an autosomal dominant inheritance pattern and is mostly associated with mutations in the LMNA gene (Lamin A/C). Two main variants have been described: the Kobberling (FPLD1) and Dunnigan (FPLD2) variants both of which differ by the involvement of fat accumulation in trunk and face. Mixed phenotypes have also been described, resulting in some of the nomenclature referring them to as one entity. FPLD share the clinical manifestations of metabolic syndrome such as insulin resistance, Acanthosis Nigricans, hypertriglyceridaemia and premature cardiovascular disease.

In pregnancy this pathophysiological continuum of insulin resistance is compounded, making management a challenge. We present a case report of a patient which highlights these challenges.

A 23 year old woman diagnosed with Dunnigan-type familial partial lipodystrophy (FPLD) attended the joint Antenatal / Endocrine clinic at 13 weeks of gestation. On examination she had a body habitus consistent with FPLD. She was diagnosed at age 7 and subsequently developed type 2 diabetes at age 11 years. She was managed initially with metformin followed by addition of insulin. In addition, her past medical history included hypothyroidism, acanthosis nigricans, chronic pancreatitis, hypertension and mixed hyperlipidaemia. Her mother and sister were also diagnosed with the kobberling-dunningham variant lipodystrophy.

It was an unplanned pregnancy and her booking HbA1c was 8.4% (IFCC 68 mmol/mol). Prior to pregnancy, she was on a basal bolus regime of Levemir and Novorapid and her total daily insulin dose was approximately 180 units. At booking, we added Metformin 500mg twice daily, which was later increased to three times daily to improve insulin sensitivity.

Her insulin requirements escalated rapidly to a total daily dose of 250 units by 25 weeks gestation. At this stage, the use of Humulin R (U500) was considered and discussed with the patient. However, she presented with vaginal spotting and went into spontaneous labour at 26 weeks. She delivered a live female infant who was admitted to the special care baby unit. During labour she was managed with intravenous sliding scale insulin. On discharge, she continued on metformin and reverted to her pre-pregnancy regime of Levemir and Novorapid.

Familial Lipodystrophy is a group of rare disorders associated with numerous metabolic complications. Diabetes, familial lipodystrophy and pregnancy in combination confer a severe insulin resistant state which if poorly controlled, can have an adverse effect on pregnancy outcome. In our patient her daily insulin requirements were rising exponentially, making it practically difficult to administer very large doses of insulin. Data on the use of U500 insulin during pregnancy is limited however there are a handful of case reports of its use in pregnancy with successful management of glycaemic and obstetric outcome.

This case is a reminder of the challenges in the glycaemic management of patients with lipodystrophy particularly in pregnancy. It also adds to the limited literature available on pregnancy outcome of patients with lipodystrophy.

References

Fig. 1. Partial lipodystrophic syndrome of Dunnigan type (FPLD2): face and neck accumulation of fat and lower limb lipodystrophy.

Annales d’Endocrinologie Volume 73 (3) 170-189 June 2012